Related Experiment Video
Updated: Mar 3, 2026
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma
Donnele Daley1, Vishnu R Mani1, Navyatha Mohan1
1S.A. Localio Laboratory, Department of Surgery, New York University School of Medicine, New York, NY 10016.
Abstract:
The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDA) is characterized by immune tolerance, which enables disease to progress unabated by adaptive immunity. However, the drivers of this tolerogenic program are incompletely defined. In this study, we found that NLRP3 promotes expansion of immune-suppressive macrophages in PDA. NLRP3 signaling in macrophages drives the differentiation of CD4+ T cells into tumor-promoting T helper type 2 cell (Th2 cell), Th17 cell, and regulatory T cell populations while suppressing Th1 cell polarization and cytotoxic CD8+ T cell activation. The suppressive effects of NLRP3 signaling were IL-10 dependent. Pharmacological inhibition or deletion of NLRP3, ASC (apoptosis-associated speck-like protein containing a CARD complex), or caspase-1 protected against PDA and was associated with immunogenic reprogramming of innate and adaptive immunity within the TME. Similarly, transfer of PDA-entrained macrophages or T cells from NLRP3-/- hosts was protective. These data suggest that targeting NLRP3 holds the promise for the immunotherapy of PDA.
Insights
NLRP3 inflammasome activation drives immune suppression in pancreatic cancer by promoting suppressive macrophages and hindering anti-tumor T cells. Inhibiting NLRP3 restores anti-tumor immunity, offering a potential pancreatic ductal adenocarcinoma immunotherapy target.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Pancreatic ductal adenocarcinoma (PDA) exhibits immune tolerance, allowing tumor progression.
- The specific mechanisms driving this immune-suppressive tumor microenvironment (TME) are not fully understood.
Purpose of the Study:
- To investigate the role of NLRP3 inflammasome in shaping the immune landscape of PDA.
- To determine if targeting NLRP3 can overcome immune tolerance and enhance anti-tumor immunity in PDA.
Main Methods:
- Utilized mouse models of PDA, genetic deletion of NLRP3 components (NLRP3, ASC, caspase-1), and pharmacological inhibition.
- Analyzed immune cell populations and function within the TME using flow cytometry and immunological assays.
- Investigated the role of IL-10 in NLRP3-mediated immune suppression.
Main Results:
- NLRP3 inflammasome activation in PDA promotes the expansion of immune-suppressive macrophages.
- NLRP3 signaling drives differentiation of CD4+ T cells towards tumor-promoting Th2 and Th17 phenotypes while suppressing Th1 and CD8+ T cell responses.
- NLRP3-mediated suppression is dependent on IL-10.
- Inhibition or genetic deletion of NLRP3, ASC, or caspase-1 conferred protection against PDA and led to immunogenic reprogramming of the TME.
Conclusions:
- NLRP3 inflammasome is a key driver of immune suppression in pancreatic ductal adenocarcinoma.
- Targeting NLRP3, ASC, or caspase-1 can reverse immune tolerance and enhance anti-tumor immunity.
- NLRP3 inhibition represents a promising therapeutic strategy for PDA immunotherapy.
More Related Videos
08:41Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity
Published on: June 7, 2017
14:15Preparation of Myeloid Derived Suppressor Cells MDSC from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting AutoMACS
Published on: June 18, 2012